Indeed, Pan-HER induced downmodulation of its targets EGFR and HER3 and their corresponding active phosphorylated forms, pEGFR and pHER3 (Fig. 5 and Additional file 2: Figures S2-S16), in agreement with previously reported results in lung and head and neck cancer cells and cetuximab-resistant non-small cell lung cancer cells [4, 16, 17]. This evidence concerns the gene EGFR and head and neck cancer.